A study shows that the Covid-19 vaccine BioNTech and Pfizer lose some effectiveness against the new variant found in South Africa. The research was done by pharmacists and scientists at the University of Texas (UTMB). The result shows a less than double reduction in antibody levels.
The study is not yet reviewed by other experts, but indicates that would be effective in neutralizing the E484K and N501Y mutations. The investigation was carried out with blood taken from those who received the vaccine. His findings are limited because he does not analyze the full set of mutations for that variant.
The findings do not indicate the need for a new dose given the variables. Pfizer and BioNTech seek to respond to a variant of SARS-CoV-2 that escapes the immunity of your vaccine. Scientists are designing a virus with the full set of mutations and expect to see results in about two weeks.
Reuters reports that study author and professor at UTMB, Pei-Yong Shi, confirmed that they evaluate options. The results are more encouraging than the study by scientists at Columbia University. That showed that the antibodies generated by the doses were significantly less effective against the South African variant.